A multi-institutional study comparing upfront SRS followed by TKI therapy, to WBRT followed by TKI therapy, to TKI therapy alone, for newly diagnosed EGFR-mutated NSCLC with brain metastases demonstrated superior outcomes with upfront SRS (median OS 46 months vs. 30 months vs. 25 months, respectively) [53]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.